ArticleFrontiers in endocrinology2026
Pain as a predictor of incident frailty in middle-aged and older adults with metabolic dysfunction-associated steatotic liver disease: a prospective cohort study using machine learning and external validation.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD), defined here by the lipid accumulation product (LAP), is common in middle-aged and older adults and linked to frailty, but factors driving frailty progression remain unclear. We examined the role of pain and depressive symptoms in incident frailty. Methods: Data came from two prospective national cohorts: the China Health and Retirement Longitudinal Study (CHARLS, 2011-2018) and the English Longitudinal Study of Ageing (ELSA, 2012-2020). Participants with MASLD and no baseline frailty were followed for 7-8 years. Three feature selection methods (LASSO, Boruta, and recursive feature elimination) identified 14 consensus predictors from 31 candidates. Nine machine learning algorithms were trained in CHARLS (70% training, 30% internal test), with ELSA reserved for external validation. Modified Poisson regression (prespecified four-model framework including baseline frailty index) estimated relative risks (RR); g-computation estimated population attributable fractions (PAF); and mediation by depressive symptoms was assessed. Net reclassification improvement (NRI) and integrated discrimination improvement (IDI) quantified the incremental value of pain. Results: The analysis included 3,622 CHARLS (median 56 years, 70% female) and 2,059 ELSA participants (median 64 years, 53% female). Frailty incidence was 24.49% (CHARLS) and 21.18% (ELSA). Logistic regression performed best (internal test AUC 0.740, 95% CI 0.706-0.774; external validation AUC 0.753, 0.728-0.779). Pain was the strongest predictor (mean absolute SHAP value 0.184). After full adjustment including baseline frailty index, pain remained associated with incident frailty (CHARLS: RR 1.219, 95% CI 1.085-1.368; ELSA: 1.310, 1.114-1.539). Under stated assumptions, the PAF was 8.01% (3.14%-12.66%) in CHARLS and 11.98% (4.76%-19.27%) in ELSA. Adding pain improved reclassification and discrimination (continuous NRI 0.397 and 0.409; IDI 0.024 and 0.023). Depressive symptoms mediated 74.0% (CHARLS) and 46.1% (ELSA) of the total effect; associations were consistent across most subgroups and strongest at baseline FI <0.10 (CHARLS: RR 1.794, 1.289-2.496; ELSA: 1.583, 1.125-2.227). Conclusion: Pain is a strong predictor of incident frailty in MASLD, with depressive symptoms as the principal mediator. Whether pain reduction modifies frailty risk requires interventional evidence. Routine pain screening could facilitate frailty risk assessment; an online calculator is provided for individualized risk prediction (https://baozhadekele.shinyapps.io/MASLD_Frailty/).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.